HIGHLIGHTS
- who: Maru00eda-Victoria Mateos et al. from the Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Cittu00e0 della Boston, MA, USA have published the paper: Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma, in the Journal: (JOURNAL)
- what: Given that current standard-of-care regimens utilize triplet and quadruplet combination regimens in the first and second lines, there will likely be a large unmet need for patients with multiple myeloma that is refractory to multiple agents in the second line and beyond [2,3,15].
- how: This . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.